Omeros (NASDAQ: OMER)
Omeros Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Omeros Company Info
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
News & Analysis
Omeros Posts 2,652 Percent Sales Jump
Why Shares of Omeros Dropped on Monday
The clinical-stage biopharmaceutical released trials data through a presentation.
Why Omeros Stock Bolted Higher This Week
A $200 million milestone payment sparked a rally in the biopharma's shares this week.
Why Omeros Corporation Stock Is Skyrocketing Today
The Omeros will now be able to fund operations at least through 2025.
Why Omeros Corporation Stock Is Marching Higher Today
A positive regulatory development is powering the biotech's shares higher today.
Why Omeros Stock Is Freefalling Today
It's reverting to where it was before its massive uptick last week.
Here's Why Omeros Is Sinking Further Today
Bad news the company received today from the FDA surprised investors more than it probably should have.
Here's Why Omeros Stock Is Tanking Today
The narsoplimab program hasn't proceeded as swimmingly as investors thought.
Valuation
Earnings Transcripts
Omeros (OMER) Q1 2020 Earnings Call Transcript
OMER earnings call for the period ending March 31, 2020.
Omeros (OMER) Q4 2019 Earnings Call Transcript
OMER earnings call for the period ending December 31, 2019.
Omeros (OMER) Q3 2019 Earnings Call Transcript
OMER earnings call for the period ending September 30, 2019.
Omeros (OMER) Q2 2019 Earnings Call Transcript
OMER earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.